Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies & High-Value Diagnostics 2015

Ranjan Perera's Biography

Ranjan Perera, Associate Professor, Scientific Director Genomics and Bioinformatics, Sanford Burnham Medical Research Institute

Dr. Perera is an Associate Professor and Scientific Director, Analytical Genomics and Bioinformatics at Sanford-Burnham Medical Research Institute. His research focuses on the molecular mechanisms by which non-coding RNAs (miRNAs and lncRNAs) might affect melanoma and prostate cancer development in humans. Prostate cancer and metastatic melanoma are both difficult cancers to detect early, and once detected late they are nearly always impossible to cure, causing mortality within three years despite surgery and conventional therapies. To find effective treatment it is imperative to understand the biology of these aggressive cancers. Prior to joining Sanford-Burnham Medical Research Institute, Dr. Perera held positions at several major biotech and pharmaceutical companies, including ISIS Pharmaceuticals and Life Technologies Corporation. He received his Ph.D. in molecular genetics from Moscow State University, Russia and University of Gent, Belgium. Dr. Perera completed his postdoctoral studies in gene targeting and DNA recombination at Massachusetts Institute of Technology (MIT).

Ranjan Perera Image

Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection: Urine as a Biofluid for Liquid Biopsies

Tuesday, 17 November 2015 at 08:00

Add to Calendar ▼

Prostate cancer is one of the leading causes of mortality among US males. There is an urgent unmet need to develop sensitive and specific biomarkers for the early detection of prostate cancer to reduce overtreatment and accompanying morbidity. We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs in prostatic adenocarcinoma tissue samples (Gleason score >6.0) and compared them with matched normal (healthy) tissues. Interestingly, these markers were also successfully detected in patient urine samples and were found to be up-regulated when compared with normal (healthy) urine.  Chromogenic in situ hybridization assay was developed to detect long noncoding RNAs in primary prostatic adenocarcinoma tissue samples, paving the way for clinical diagnostics. We believe that these results will set the stage for more extensive studies to develop novel long noncoding RNA-based diagnostic assays for early prostate cancer detection and will help to distinguish benign prostate cancer from precancerous lesions.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid Biopsies and High-Value Diagnostics 2015Biofluid Biopsies and High-Value Diagnostics 2015 in Boston, USABoston,